SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 5, 2003
REGENERON PHARMACEUTICALS, INC.
| NEW YORK | 0-19034 | No. 13-3444607 | ||
|
|
||||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY | 10591-6707 | |
|
|
||
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code | (914) 347-7000 | ||
|
|
NOT APPLICABLE
Page 1 of 9
| INFORMATION TO BE INCLUDED IN REPORT | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| Item 12. Results of Operations and Financial Condition. | ||||||||
| SIGNATURE | ||||||||
| PRESS RELEASE | ||||||||
INFORMATION TO BE INCLUDED IN REPORT
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits | |
| 99(a) Press Release dated May 5, 2003. |
Item 12. Results of Operations and Financial Condition.
On May 5, 2003, we reported our first quarter 2003 results. Our first quarter 2003 results are discussed in detail in the press release attached hereto as Exhibit 99(a), which is incorporated by reference in its entirety. The information furnished under Item 12 of this Current Report on Form 8-K, including Exhibit 99(a), shall be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended and incorporated by reference in any of our filings under the Securities Act of 1933, as amended, as may be specified in such filing.
-2-
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Regeneron Pharmaceuticals, Inc. | ||
| By: /s/ Stuart Kolinski | ||
|
Stuart Kolinski Vice President & General Counsel |
||
| Date: May 5, 2003 |
-3-